Company: RGBP
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012619
Chunk: 10

Company: Regen BioPharma Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 1
Chunk 10
---
consisted of the following:

SCHEDULE OF INVESTMENT

                                                               As of                          As of                      
                                                                                                                         
                                                               March 31,2025                  September 30,              
                                                                                              2024                       
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  470,588 Common Shares of Zander Therapeutics, Inc.           $                   6,495      $                   6,495  
  725,000 Series M Preferred of Zander Therapeutics, Inc.                         11,238                         11,238  
  Investments, net                                             $                  17,733      $                  17,333  

Common
Shares of Zander Therapeutics, Inc.

On
June 11, 2018, Regen Biopharma, Inc. was paid a property dividend consisting of 470,588
Basis Fair Value Total Unrealized Gains/(Loss)
─────────────────────────────────────────────────────────────────────────────────────────────────
$ 87,608 $ 6,495 $ ( 81,112
Series
M Preferred of Zander Therapeutics, Inc.
On
November 29, 2018, the Company accepted 725,000 13,124
Basis Fair Value Total Unrealized Gains/(Loss)
────────────────────────────────────────────────────────────────────────────────────────────────────
$ 134,971 $ 11,238 $ ( 123,733
On
March 31, 2025 and September 30, 2024, the Company revalued 470,588 725,000
Fair Value of Intellectual Property 300,000
Prepaid Expenses 65,661
Due from Employee -
Note Receivable 40000
Accrued Interest Receivable 35,000
Investment Securities 258,255
Convertible Note Receivable 10,000
Accounts Payable 30,563
Notes Payable 400,000
Accrued Expenses Related Parties 162,011
Notes Payable Related Party -
Accrued Expenses 647,072
Enterprise Value 1,948,562
Less: Total Debt ( 1,239,646
Portion of Enterprise Value Attributable to Shareholders 708,916
Fair Value per Shares 0.0155

The
abovementioned constitute the Company’s sole related party investment securities as of March 31, 2025.

5. ACCRUED EXPENSES

Accrued